ナフチドロフリル

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Naftidrofuryl increases the peripheric circulation of blood, e.g. in peripheral vascular disease (PAOD), Raynaud's phenomenon, cerebrovascular diseases, diffuse circulatory insufficiency in the elderly going along with confusion or behavioral disturbances. Overdosage may result in disturbance of the atrioventricular conduction time, ventricular arrhythmia, convulsions, acute renal failure or acute hepatic necrosis (A302).

Naftidrofuryl blocks the type 2 serotonin (5-HT2) receptors and thereby inhibits the effects of serotonin-induced vasoconstriction or platelet aggregation. It is also a stimulator of metabolism by improving aerobic glucose metabolism and by these means preserving cell function in ischemic conditions. Overdosage may result in disturbance of the atrioventricular conduction time, ventricular arrhythmia, convulsions, acute renal failure or acute hepatic necrosis (A302).

C04AX21

C - Cardiovascular system

QC - Cardiovascular system

Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.

Drugs used to cause dilation of the blood vessels.

Use (kg; approx.) in Germany (2009): >5000

Naftidrofuryl is a drug used in the management of peripheral and cerebral vascular disorders (L999).